KalVista Pharmaceuticals Quarterly Income Statements Chart
Quarterly
|
Annual
KalVista Pharmaceuticals Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 | 2024-01-31 | 2023-10-31 | 2023-07-31 | 2023-04-30 | 2023-01-31 | 2022-10-31 | 2022-07-31 | 2022-04-30 | 2022-01-31 | 2021-10-31 | 2021-07-31 | 2021-04-30 | 2021-01-31 | 2020-10-31 | 2020-07-31 | 2020-04-30 | 2020-01-31 | 2019-10-31 | 2019-07-31 | 2019-04-30 | 2019-01-31 | 2018-10-31 | 2018-07-31 | 2018-04-30 | 2018-01-31 | 2017-10-31 | 2017-07-31 | 2017-04-30 | 2017-01-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| product revenue | 1,426,000 | |||||||||||||||||||||||||||||||||||||||||
| operating expenses: | ||||||||||||||||||||||||||||||||||||||||||
| cost of revenue | 590,000 | |||||||||||||||||||||||||||||||||||||||||
| gross profit | ||||||||||||||||||||||||||||||||||||||||||
| yoy | ||||||||||||||||||||||||||||||||||||||||||
| qoq | ||||||||||||||||||||||||||||||||||||||||||
| gross margin % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | ||||||||||||||||||||||
| research and development | 15,162,000 | 15,891,000 | 12,594,000 | 16,610,000 | 26,614,000 | 25,248,000 | 22,523,000 | 19,089,000 | 19,307,000 | 23,951,000 | 20,063,000 | 18,077,000 | 18,186,000 | 19,213,000 | 19,738,000 | 17,546,000 | 13,669,000 | 11,877,000 | 9,097,000 | 9,148,000 | 11,165,000 | 9,485,000 | 11,233,000 | 9,789,000 | 9,686,000 | 5,970,500 | 7,650,000 | 7,876,000 | 8,356,000 | 3,096,250 | 4,548,000 | 4,361,000 | 3,476,000 | 2,417,500 | 3,339,000 | 332,000 | 947,000 | 3,532,000 | 4,260,000 | 3,533,000 | 4,504,000 | 3,902,000 |
| selling, general and administrative | 44,683,000 | |||||||||||||||||||||||||||||||||||||||||
| total operating expenses | 60,435,000 | 55,030,000 | 42,940,000 | 45,811,000 | 44,215,000 | 48,455,000 | 33,151,000 | 29,746,000 | 29,093,000 | 31,728,000 | 26,945,000 | 25,883,000 | 26,316,000 | 26,811,000 | 26,683,000 | 23,603,000 | 19,516,000 | 18,042,000 | 12,657,000 | 12,781,000 | 14,443,000 | 12,781,000 | 14,301,000 | 13,209,000 | 12,933,000 | 14,186,000 | 10,550,000 | 10,485,000 | 10,727,000 | 7,809,000 | 6,677,000 | 7,064,000 | 5,549,000 | 5,200,000 | 8,365,000 | 2,412,000 | 6,971,000 | 6,535,000 | 5,577,000 | 4,906,000 | 5,674,000 | 4,908,000 |
| operating income | -59,009,000 | -55,030,000 | -42,940,000 | -45,811,000 | -44,215,000 | -48,455,000 | -33,151,000 | -29,746,000 | -29,093,000 | -31,728,000 | -26,945,000 | -25,883,000 | -26,316,000 | -26,811,000 | -26,683,000 | -23,603,000 | -19,516,000 | -18,042,000 | -12,657,000 | -12,781,000 | -14,443,000 | -8,957,000 | -12,724,000 | -9,289,000 | -9,564,000 | -11,260,000 | -6,660,000 | -4,893,000 | -7,009,000 | -2,969,000 | -4,346,000 | -5,937,000 | -5,453,000 | -5,086,000 | -8,117,000 | |||||||
| yoy | 33.46% | 13.57% | 29.53% | 54.01% | 51.98% | 52.72% | 23.03% | 14.92% | 10.55% | 18.34% | 0.98% | 9.66% | 34.84% | 48.60% | 110.82% | 84.67% | 35.12% | 101.43% | -0.53% | 37.59% | 51.01% | -20.45% | 91.05% | 89.84% | 36.45% | 279.25% | 53.24% | -17.58% | 28.53% | -41.62% | -46.46% | |||||||||||
| qoq | 7.23% | 28.16% | -6.27% | 3.61% | -8.75% | 46.16% | 11.45% | 2.24% | -8.30% | 17.75% | 4.10% | -1.65% | -1.85% | 0.48% | 13.05% | 20.94% | 8.17% | 42.55% | -0.97% | -11.51% | 61.25% | -29.61% | 36.98% | -2.88% | -15.06% | 69.07% | 36.11% | -30.19% | 136.07% | -31.68% | -26.80% | 8.88% | 7.22% | -37.34% | ||||||||
| operating margin % | -17196.88% | -8709.94% | -27268.45% | -7142.97% | -17214.79% | -39784.33% | -1509.52% | 11824.04% | 4310.66% | 10217.75% | 34238.60% | -11734.63% | -1837.01% | 3792.58% | -5491.63% | -6586.03% | -15517.07% | -1776.10% | 4540.32% | -4933.33% | ||||||||||||||||||||||
| other income: | ||||||||||||||||||||||||||||||||||||||||||
| interest income | 1,849,000 | 1,992,000 | 1,394,000 | 1,357,000 | 1,692,000 | 1,513,000 | 684,000 | 776,000 | 923,000 | 808,000 | 732,000 | 449,000 | 242,000 | 268,000 | 258,000 | 290,000 | 274,000 | 314,000 | 137,000 | 193,000 | 259,000 | 363,000 | 372,000 | 505,000 | 590,000 | 381,000 | 723,000 | 204,000 | 89,000 | 65,000 | 14,000 | 1,000 | 2,000 | 5,000 | 7,000 | 19,000 | 20,000 | 12,000 | 1,000 | 2,000 | 2,000 | |
| interest expense | -3,522,000 | -406,000 | -88,000 | -88,000 | -95,000 | -169,000 | -836,000 | |||||||||||||||||||||||||||||||||||
| foreign currency exchange gain | 1,925,000 | 2,882,000 | -983,000 | 67,000 | 514,000 | -139,000 | 1,120,000 | 456,000 | 327,000 | 597,000 | -317,000 | -517,000 | -1,008,000 | -198,000 | -280,000 | -51,000 | 132,000 | 301,000 | -24,000 | 438,000 | -612,000 | 138,000 | 560,000 | -453,000 | 20,750 | 248,000 | -231,000 | 67,000 | -459,000 | -1,887,000 | 83,000 | -32,000 | 377,750 | -195,000 | ||||||||
| other income | 818,000 | 1,198,500 | 1,109,000 | 2,119,000 | 1,566,000 | 1,833,750 | 2,319,000 | 2,619,000 | 2,397,000 | 2,838,500 | 4,313,000 | 3,494,000 | 3,549,000 | 3,438,000 | 4,156,000 | 3,943,000 | 3,184,000 | 2,640,000 | 2,171,000 | 2,186,000 | 2,932,000 | 2,498,000 | 2,923,000 | 2,321,000 | 2,089,000 | 2,511,000 | 1,733,000 | 1,616,000 | 1,823,000 | 1,985,000 | 985,000 | 867,000 | 555,000 | 1,019,000 | 661,000 | 1,000 | -3,000 | -3,000 | 1,000 | -1,000 | 553,000 | |
| total other income | 1,070,000 | 1,949,000 | -1,322,000 | 3,543,000 | 3,772,000 | 3,806,000 | 4,123,000 | 2,096,000 | 3,776,000 | 5,423,000 | 5,642,000 | 3,626,000 | 3,274,000 | 2,698,000 | 4,216,000 | 3,953,000 | 3,407,000 | 3,086,000 | 2,609,000 | 2,355,000 | 3,629,000 | 2,249,000 | 3,433,000 | 3,386,000 | 2,226,000 | 2,858,000 | 2,704,000 | 1,589,000 | 1,979,000 | 2,312,000 | -888,000 | 951,000 | 525,000 | 884,000 | 473,000 | -3,345,000 | -283,000 | |||||
| income before income taxes | -57,939,000 | |||||||||||||||||||||||||||||||||||||||||
| income tax expense | 2,157,000 | |||||||||||||||||||||||||||||||||||||||||
| net income | -60,096,000 | -52,226,000 | -48,509,000 | -42,268,000 | -40,443,000 | -44,649,000 | -29,028,000 | -27,650,000 | -25,317,000 | -26,305,000 | -21,303,000 | -22,257,000 | -23,042,000 | -24,113,000 | -22,467,000 | -19,650,000 | -16,109,000 | -14,956,000 | -10,048,000 | -10,426,000 | -10,814,000 | -6,584,000 | -9,291,000 | -5,903,000 | -7,338,000 | -8,526,000 | -3,956,000 | -3,304,000 | -5,030,000 | -657,000 | -5,234,000 | -4,986,000 | -4,928,000 | -4,202,000 | -7,644,000 | |||||||
| yoy | 48.59% | 16.97% | 67.11% | 52.87% | 59.75% | 69.74% | 36.26% | 24.23% | 9.87% | 9.09% | -5.18% | 13.27% | 43.04% | 61.23% | 123.60% | 88.47% | 48.96% | 127.16% | 8.15% | 76.62% | 47.37% | -22.78% | 134.86% | 78.66% | 45.88% | 1197.72% | -24.42% | -33.73% | 2.07% | -84.36% | -31.53% | |||||||||||
| qoq | 15.07% | 7.66% | 14.77% | 4.51% | -9.42% | 53.81% | 4.98% | 9.22% | -3.76% | 23.48% | -4.29% | -3.41% | -4.44% | 7.33% | 14.34% | 21.98% | 7.71% | 48.85% | -3.63% | -3.59% | 64.25% | -29.14% | 57.39% | -19.56% | -13.93% | 115.52% | 19.73% | -34.31% | 665.60% | -87.45% | 4.97% | 1.18% | 17.28% | -45.03% | ||||||||
| net income margin % | -16320.63% | -9839.55% | -25159.52% | -6533.60% | -14980.47% | -32984.33% | -1193.45% | 10634.18% | 3629.56% | 8506.49% | 28261.40% | -9727.48% | -1458.35% | 3093.77% | -4111.79% | -4841.18% | -11330.49% | -1128.68% | 3437.90% | -2930.37% | ||||||||||||||||||||||
| other comprehensive income: | ||||||||||||||||||||||||||||||||||||||||||
| foreign currency translation loss | -604,000 | -419,000 | ||||||||||||||||||||||||||||||||||||||||
| unrealized holding gain on marketable securities | 18,000 | 276,000 | 367,000 | 651,000 | 1,064,000 | 21,000 | 438,000 | 440,000 | 392,000 | 458,000 | 658,000 | 52,000 | 98,000 | -295,000 | -129,000 | -54,250 | -48,000 | -164,000 | -5,000 | |||||||||||||||||||||||
| reclassification adjustment for realized gain on marketable securities included in net income | -587,000 | 21,000 | -1,000 | 69,000 | 16,000 | 74,000 | 176,000 | 97,000 | 23,000 | |||||||||||||||||||||||||||||||||
| total other comprehensive income | -1,173,000 | |||||||||||||||||||||||||||||||||||||||||
| comprehensive loss | -61,269,000 | -55,232,000 | -48,016,000 | -42,100,000 | -39,824,000 | -44,844,000 | -28,857,000 | -28,224,000 | -23,433,000 | -23,331,000 | -25,635,000 | -23,086,000 | -19,881,000 | -16,166,000 | -15,121,000 | -9,359,000 | -10,763,000 | -10,551,000 | -7,084,000 | -9,209,000 | -5,380,000 | -7,399,000 | -8,351,000 | -3,821,000 | -3,111,000 | -6,350,000 | -1,630,000 | -2,800,000 | -5,029,000 | -3,938,000 | -7,478,000 | |||||||||||
| net income per share | -1.12 | -0.99 | -0.92 | -0.91 | -0.87 | -1.07 | -0.84 | -0.8 | -0.74 | -0.75 | -0.75 | -0.9 | -0.94 | -0.98 | -0.92 | -0.8 | -0.66 | -0.67 | -0.56 | -0.58 | -0.61 | -0.37 | -0.52 | -0.33 | -0.42 | -0.53 | -0.23 | -0.22 | -0.47 | -0.04 | -0.49 | -0.5 | -0.51 | 1.03 | -1.03 | -0.09 | -0.28 | -0.25 | -0.18 | -0.19 | -0.37 | -7.38 |
| weighted-average common shares outstanding, basic and diluted | 53,497,128 | 49,652,878 | 52,638,888 | 46,695,220 | 46,232,977 | 36,786,575 | 34,723,379 | 34,565,955 | 34,414,226 | 27,890,846 | 28,278,453 | 24,595,039 | 24,557,615 | 24,473,092 | 24,479,660 | 24,439,623 | 24,429,919 | 19,094,440 | 17,961,802 | 17,907,393 | 17,848,583 | 17,748,666 | 17,838,872 | 17,823,302 | 17,488,997 | 15,080,863 | 17,231,449 | 15,108,272 | 10,799,895 | 10,321,780 | 10,788,556 | 10,003,963 | 9,713,042 | 4,646,764 | 7,657,874 | 26,343,108 | 26,334,622 | 26,332,494 | 19,082,604 | 26,322,494 | 24,303,819 | 701,980 |
| general and administrative | 39,139,000 | 30,346,000 | 29,201,000 | 17,601,000 | 23,207,000 | 10,628,000 | 10,657,000 | 9,786,000 | 7,777,000 | 6,882,000 | 7,806,000 | 8,130,000 | 7,598,000 | 6,945,000 | 6,057,000 | 5,847,000 | 6,165,000 | 3,560,000 | 3,633,000 | 3,278,000 | 3,296,000 | 3,068,000 | 3,420,000 | 3,247,000 | 1,969,750 | 2,900,000 | 2,609,000 | 2,371,000 | 1,726,250 | 2,129,000 | 2,703,000 | 2,073,000 | 2,243,250 | 5,026,000 | 2,080,000 | 2,604,000 | 1,543,000 | 1,317,000 | 1,373,000 | 1,170,000 | 1,006,000 | |
| interest expense related to the sale of future royalties | -710,500 | -2,842,000 | ||||||||||||||||||||||||||||||||||||||||
| net income before income taxes | -31,742,750 | -44,262,000 | ||||||||||||||||||||||||||||||||||||||||
| benefit from income taxes | 1,061,750 | 4,247,000 | ||||||||||||||||||||||||||||||||||||||||
| foreign currency translation gain | 97,500 | 352,000 | 166,000 | -128,000 | -93,250 | -46,000 | 91,000 | -31,000 | 1,128,000 | -1,297,000 | -403,000 | |||||||||||||||||||||||||||||||
| reclassification adjustment for realized (gain) on marketable securities included in net income | -298,000 | -226,000 | -649,000 | -48,000 | -76,000 | -46,000 | -70,000 | |||||||||||||||||||||||||||||||||||
| other comprehensive income | 320,000 | 493,000 | 168,000 | 619,000 | 169,000 | 79,750 | 1,785,000 | -226,750 | -619,000 | -231,000 | -57,000 | 153,750 | 689,000 | -337,000 | 263,000 | 136,000 | 82,000 | 523,000 | -248,000 | 135,000 | ||||||||||||||||||||||
| revenue | 3,824,000 | 1,577,000 | 3,920,000 | 3,369,000 | 2,926,000 | 3,890,000 | 5,592,000 | 3,718,000 | 4,840,000 | 2,331,000 | 1,127,000 | |||||||||||||||||||||||||||||||
| yoy | 30.69% | -59.46% | -29.90% | -9.39% | -39.55% | 66.88% | 396.18% | |||||||||||||||||||||||||||||||||||
| qoq | 142.49% | -59.77% | 16.36% | 15.14% | -24.78% | -30.44% | 50.40% | -23.18% | 107.64% | 106.83% | ||||||||||||||||||||||||||||||||
| reclassification adjustment for realized (gain) loss on marketable securities included in net income | -317,000 | -282,500 | -221,000 | -595,000 | -314,000 | |||||||||||||||||||||||||||||||||||||
| other comprehensive gain | -58,250 | 171,000 | ||||||||||||||||||||||||||||||||||||||||
| foreign currency exchange loss | -1,299,000 | |||||||||||||||||||||||||||||||||||||||||
| other comprehensive loss | -574,000 | -1,176,000 | -289,000 | -61,000 | ||||||||||||||||||||||||||||||||||||||
| comprehensive | -25,148,000 | |||||||||||||||||||||||||||||||||||||||||
| comprehensive income | -16,570,750 | -19,518,000 | -4,812,000 | |||||||||||||||||||||||||||||||||||||||
| foreign currency translation adjustments | -107,500 | -445,000 | -33,000 | 49,000 | 52,000 | 813,000 | -127,000 | 338,000 | -489,000 | 142,000 | 495,000 | -89,000 | -33,000 | -97,000 | 193,000 | -1,320,000 | -973,000 | 2,434,000 | -43,000 | 116,000 | ||||||||||||||||||||||
| unrealized holding loss on marketable securities | -193,250 | -350,000 | ||||||||||||||||||||||||||||||||||||||||
| unrealized holding gains on available-for-sale securities | 60,000 | 40,000 | 28,000 | 28,000 | 208,000 | 232,000 | ||||||||||||||||||||||||||||||||||||
| reclassification adjustment for realized (gain) on available-for-sale securities included in net income | -57,250 | -100,000 | ||||||||||||||||||||||||||||||||||||||||
| other comprehensive loss: | ||||||||||||||||||||||||||||||||||||||||||
| grant income | 96,000 | 114,000 | 248,000 | |||||||||||||||||||||||||||||||||||||||
| currency translation adjustments | -708,000 | 166,000 | ||||||||||||||||||||||||||||||||||||||||
| license revenue | 7,000 | 7,000 | 7,000 | 8,000 | 7,000 | 7,000 | 7,000 | |||||||||||||||||||||||||||||||||||
| restructuring and lease termination charges | 3,420,000 | |||||||||||||||||||||||||||||||||||||||||
| impairment of long-lived assets | 1,460,000 | |||||||||||||||||||||||||||||||||||||||||
| income from operations | -2,405,000 | -6,964,000 | -6,528,000 | -5,569,000 | -4,899,000 | -5,667,000 | -4,901,000 | |||||||||||||||||||||||||||||||||||
| loss on extinguishment of convertible promissory notes | -3,177,000 | |||||||||||||||||||||||||||||||||||||||||
| net income and comprehensive loss | -2,385,000 | -7,350,000 | -6,607,000 | -5,659,000 | -4,991,000 | -9,012,000 | -5,184,000 | |||||||||||||||||||||||||||||||||||
| revised from a net income of 1.12 per share to common stockholders, basic and diluted, and 17,203,279 weighted-average common shares outstanding, basic and diluted, as previously reported for the nine months ended september 30, 2015. | ||||||||||||||||||||||||||||||||||||||||||
| revised from a net income per share to common stockholders, basic and diluted, of 0.37 per share and 24,303,819 weighted-average common shares outstanding, basic and diluted, as previously reported for the three months ended june 30, 2015, and a net income of 1.13 per share to common stockholders, basic and diluted, and 12,568,098 weighted-average common shares outstanding, basic and diluted, as previously reported for the six months ended june 30, 2015. | ||||||||||||||||||||||||||||||||||||||||||
| net income attributable to common stockholders | -5,184,000 |
We provide you with 20 years income statements for KalVista Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of KalVista Pharmaceuticals stock. Explore the full financial landscape of KalVista Pharmaceuticals stock with our expertly curated income statements.
The information provided in this report about KalVista Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.